Difference between revisions of "Tisagenlecleucel (Kymriah)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== *From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=736184 NCI Drug Dictionary]: Autologous T lymphocytes transduced with a m...") |
m |
||
| Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[B-cell acute lymphoblastic leukemia]] | *[[B-cell acute lymphoblastic leukemia]] | ||
| + | *[[Diffuse large B-cell lymphoma]] | ||
| + | *[[Transformed lymphoma]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *8/30/ | + | *8/30/2017: Granted [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574154.htm FDA regular approval] "for the treatment of patients up to age 25 years with [[B-cell acute lymphoblastic leukemia|B-cell precursor acute lymphoblastic leukemia (ALL)]] that is refractory or in second or later relapse." |
| + | *5/1/2018: FDA approval expanded "for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL) not otherwise specified]], high grade B-cell lymphoma and [[Transformed lymphoma|DLBCL arising from follicular lymphoma]]." | ||
==Also known as== | ==Also known as== | ||
| Line 18: | Line 21: | ||
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
| + | [[Category:Diffuse large B-cell lymphoma medications]] | ||
| + | [[Category:Transformed lymphoma medications]] | ||
[[Category:REMS program]] | [[Category:REMS program]] | ||
[[Category:Drugs FDA approved in 2017]] | [[Category:Drugs FDA approved in 2017]] | ||
Revision as of 14:06, 3 May 2018
Mechanism of action
- From the NCI Drug Dictionary: Autologous T lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel direct the T lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 8/30/2017: Granted FDA regular approval "for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse."
- 5/1/2018: FDA approval expanded "for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma."
Also known as
- Code name: CTL019
- Generic name: tisagenlecleucel-T
- Brand name: Kymriah